Aerpio Pharmaceuticals

Brandi Soldo

PhD, DABT – Vice-President, Toxicology

Brandi is a diplomat of the American Board of Toxicology with 18 years of nonclinical toxicology experience. Dr. Soldo leads nonclinical exploratory safety/PK and GLP IND-enabling through Phase 3-support ADME, safety pharmacology, carcinogenicity, and general, genetic, and reproductive toxicology studies for Aerpio’s AKB-9778 Tie2- and AKB-4924 HIF1-activator projects. She also led all nonclinical ADME and toxicology studies for AKB-6548, Akebia’s lead HIF2 activator treatment for anemia. Prior to joining Akebia in 2008, Dr. Soldo was a Senior Principal Scientist in Drug Safety at Parke-Davis/Pfizer, developed the hERG electrophysiology laboratories at the Pfizer Ann Arbor facility, and was a Drug Safety project representative for Pfizer CNS programs. Dr. Soldo received her B.S. in Biomedical Engineering at the University of California, San Diego, earned her Ph.D. from the University of Colorado Health Science Center in Pharmacology, and performed post-doctoral research on electrophysiological mechanisms in the CNS at the University of Michigan and Parke Davis/Warner Lambert.